CD177 and neoplasm: In recent years, there has been a rising interest in utilizing the coupling of PS with NPs to enhance tumor selectivity and targeting while minimizing adverse effects.[142] A promising approach is the development of nanoparticle‐conjugated PS that can exploit tumor‐specific cell surface receptors to directly deliver the PS to tumor cells.[143] To address the limited penetration of light wavelengths through brain tissue required for optimal activation, researchers are developing NPs activated by near‐infrared light.